Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venlafaxine for prevention of oxaliplatin-induced peripheral neuropathy
NL-OMON42624Phase 3Not yet recruiting
- Sponsor
- Maasstad Ziekenhuis
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in peripheral neuropathy, chemotherapy-induced peripheral neuropathy (CIPN) and peripheral neuropathy (CIPN) comparing Venlafaxine XR with Matching placebo (2 arms). Planned start Feb 2016; status: not yet recruiting.
02
Drugs
venlafaxine
03
Conditions
peripheral neuropathychemotherapy-induced peripheral neuropathy (CIPN)peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NL-OMON42624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42624.